{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:22:49Z","timestamp":1789636969853,"version":"4.0.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"JPM-MCS","award":["B.09"],"award-info":[{"award-number":["B.09"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.antiviral.2017.12.020","type":"journal-article","created":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T02:47:49Z","timestamp":1514429269000},"page":"50-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus"],"prefix":"10.1016","volume":"151","author":[{"given":"Sandra L.","family":"Bixler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Bocan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly S.","family":"Wetzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean A.","family":"Van Tongeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5754-6192","authenticated-orcid":false,"given":"Lisa H.","family":"Cazares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Soloveva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Fang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Giesing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8844-353X","authenticated-orcid":false,"given":"Robert","family":"Lenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Bavari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis K.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"63","key":"10.1016\/j.antiviral.2017.12.020_bib1","first-page":"1288","article-title":"Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone","volume":"2016","author":"Bai","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.12.020_bib2","article-title":"Efficacy of favipiravir (T-705) in non-human primates infected with Ebola virus and Marburg virus","author":"Bixler","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.020_bib3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1086\/515386","article-title":"A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever","volume":"178","author":"Bray","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.12.020_bib4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev-pharmtox-010716-105055","article-title":"Will there Be a cure for Ebola?","volume":"57","author":"Cardile","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.antiviral.2017.12.020_bib5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.12.020_bib6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.020_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068347","article-title":"The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase","volume":"8","author":"Jin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2017.12.020_bib8","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1073\/pnas.0909603107","article-title":"T-705 (favipiravir) activity against lethal H5N1 influenza A viruses","volume":"107","author":"Kiso","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2017.12.020_bib9","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/AAC.01219-10","article-title":"T-705 (favipiravir) inhibition of arenavirus replication in cell culture","volume":"55","author":"Mendenhall","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.12.020_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005389","article-title":"Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted","volume":"11","author":"Nguyen","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.antiviral.2017.12.020_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.020_bib12","unstructured":"Review Report. Pharmaceuticals and Medical Devices Agency; 2014."},{"key":"10.1016\/j.antiviral.2017.12.020_bib13","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2017.12.020_bib14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/dkp274","article-title":"Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells","volume":"64","author":"Smee","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2017.12.020_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.020_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217307246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217307246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T21:54:07Z","timestamp":1535147647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354217307246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":16,"alternative-id":["S0166354217307246"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.12.020","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}